Biotech IPO window is opening but big pharma M&A still leaders, top bankers say
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
